Cambridge, MA – According to filings with the U.S. Securities and Exchange Commission, Torque Therapeutics is raising $38,275,890.00 in a new round of investment. Sources indicate as part of senior management President and Chief Executive Officer, Bart Henderson played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Torque Therapeutics

Torque is developing a new class of Deep-Primed T cell therapeutics to dramatically expand cell therapy cures for cancer. Deep-Primed T cells both target multiple tumor antigens and pharmacologically activate an immune response with anchored cytokines. This process does not require genetic engineering of the T cells and so preserves the natural T cell receptor for delivering a regulated immune response, with the potential for a high margin of safety.

To learn more about Torque Therapeutics, visit http://www.torquetx.com/

Contact:
Bart Henderson, President and Chief Executive Officer
617-863-3650
https://www.linkedin.com/in/bart-henderson-536b99b/

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved